Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports

References

• Wakayama K, Kamiyama T, Yokoo H, et al. Huge hepatocellular carcinoma greater than 10 cm in diameter worsens prognosis by causing distant recurrence after curative resection. J Surg Oncol. 2017;115(3):324–329. doi:10.1002/jso.24501
   PubMed Web of Science ®Google Scholar
• Yang B, Li CL, Guo WH, et al. Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus. BMC Cancer. 2018;18(1):101. doi:10.1186/s12885-018-3989-2
   PubMedGoogle Scholar
• Huang YH, Wu JC, Chen SC, et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther. 2006;23(1):129–135. doi:10.1111/j.1365-2036.2006.02704.x
   PubMed Web of Science ®Google Scholar
• Ueshima K, Kudo M, Takita M, et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology. 2010;78(Suppl 1):148–153. doi:10.1159/000315244
   PubMedGoogle Scholar
• Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy. Liver Cancer. 2015;4(3):188–199. doi:10.1159/000367746
   PubMed Web of Science ®Google Scholar
• Long Y, Song X, Guan Y, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;38(4):486–495.
   Web of Science ®Google Scholar
• Mei J, Tang YH, Wei W, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma. Front Oncol. 2021;11:618206. doi:10.3389/fonc.2021.618206
   PubMed Web of Science ®Google Scholar
• Huang W, You L, Yang S, et al. Metronomic S-1 chemotherapy plus transcatheter arterial chemoembolization (TACE): a promising treatment of hepatocellular carcinoma refractory to TACE. J BUON. 2016;21(4):909–916.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized Phase II trial. Ann Oncol. 2016;27(11):2090–2096. doi:10.1093/annonc/mdw323
   PubMed Web of Science ®Google Scholar
• Hu J, Bao Q, Cao G, et al. Hepatic arterial infusion chemotherapy using oxaliplatin plus 5-fluorouracil versus transarterial chemoembolization/embolization for the treatment of advanced hepatocellular carcinoma with major portal vein tumor thrombosis. Cardiovasc Intervent Radiol. 2020;43(7):996–1005. doi:10.1007/s00270-019-02406-3
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62–67. doi:10.1002/hep.510290145
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711. doi:10.1093/jnci/djn134
   PubMedGoogle Scholar
• Kim GA, Shim JH, Yoon SM, et al. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. J Vasc Interv Radiol. 2015;26(3):320–329 e326. doi:10.1016/j.jvir.2014.10.019
   PubMed Web of Science ®Google Scholar
• Koo JE, Kim JH, Lim YS, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys. 2010;78(1):180–187. doi:10.1016/j.ijrobp.2009.07.1730
   PubMed Web of Science ®Google Scholar
• Pavlek G, Romic I, Juzbasic K, et al. Case report: urgent liver pathologies: all in one. Front Surg. 2022;9:940856. doi:10.3389/fsurg.2022.940856
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–1171. doi:10.1053/jhep.2002.33156
   PubMed Web of Science ®Google Scholar
• Shi M, Lu LG, Fang WQ, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst. 2013;105(1):59–68. doi:10.1093/jnci/djs464
   PubMedGoogle Scholar
• Zhang H, Zeng X, Peng Y, Tan C, Wan X. Cost-effectiveness analysis of hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization in patients with large unresectable hepatocellular carcinoma. Front Pharmacol. 2022;13:849189. doi:10.3389/fphar.2022.849189
   PubMed Web of Science ®Google Scholar
• Li S, Lyu N, Han X, et al. Hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: a propensity score-matching analysis. J Vasc Interv Radiol. 2021;32(9):1267–1276 e1261. doi:10.1016/j.jvir.2021.06.008
   PubMed Web of Science ®Google Scholar
• He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021;13:17588359211002720. doi:10.1177/17588359211002720
   Web of Science ®Google Scholar
• Luo L, Xiao Y, Zhu G, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a tertiary medical center experience. Front Oncol. 2022;12:1004652. doi:10.3389/fonc.2022.1004652
   PubMed Web of Science ®Google Scholar
• Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends. 2021;15(3):155–160. doi:10.5582/bst.2021.01091
   PubMed Web of Science ®Google Scholar
• Guo W, Gao J, Zhuang W, Wu Z, Li B, Chen S. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: a propensity score-matching cohort study. JGH Open. 2020;4(3):477–483. doi:10.1002/jgh3.12285
   PubMed Web of Science ®Google Scholar
• Kondo Y, Fukuda R. 肝細胞癌治療における肝動注療法の最先端 [Cutting edge of hepatic artery infusion chemotherapy for hepatocellular carcinoma]. Gan To Kagaku Ryoho. 2020;47(1):1–5. Japanese.
   PubMedGoogle Scholar
• Ahn YE, Suh SJ, Yim HJ, et al. Comparison of sorafenib versus hepatic arterial infusion chemotherapy-based treatment for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Gut Liver. 2021;15(2):284–294. doi:10.5009/gnl19367
   PubMed Web of Science ®Google Scholar
• Moriguchi M, Aramaki T, Nishiofuku H, et al. Sorafenib versus hepatic arterial infusion chemotherapy as initial treatment for hepatocellular carcinoma with advanced portal vein tumor thrombosis. Liver Cancer. 2017;6(4):275–286. doi:10.1159/000473887
   PubMed Web of Science ®Google Scholar
• He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953–960. doi:10.1001/jamaoncol.2019.0250
   PubMed Web of Science ®Google Scholar
• Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized Phase III trial. J Clin Oncol. 2022;40(2):150–160. doi:10.1200/JCO.21.00608
   PubMed Web of Science ®Google Scholar
• Mathew M, Enzler T, Shu CA, Rizvi NA. Combining chemotherapy with PD-1 blockade in NSCLC. Pharmacol Ther. 2018;186:130–137. doi:10.1016/j.pharmthera.2018.01.003
   PubMed Web of Science ®Google Scholar
• Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747. doi:10.1155/2014/638747
   PubMedGoogle Scholar
• Courau T, Nehar-Belaid D, Florez L, et al. TGF-beta and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. JCI Insight. 2016;1(9):e85974. doi:10.1172/jci.insight.85974
   PubMed Web of Science ®Google Scholar
• Lv Y, Liang R, Hu X, et al. Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma. Pharmazie. 2014;69(10):759–763.
   PubMed Web of Science ®Google Scholar
• Liu B, Ying J, Luo C, Xu Q, Zhu L, Zhong H. S-1 combined with oxaliplatin as first line chemotherapy for Chinese advanced gastric cancer patients. Hepatogastroenterology. 2012;59(114):649–653. doi:10.5754/hge11893
   PubMedGoogle Scholar